The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• The tumor suppressor in lung cancer-1 (TSLC1) gene is frequently silenced in human lung carcinomas.
• TSLC1 encodes Necl-2, a cell-surface protein involved in epithelial cell junctions, inhibiting tumorigenesis by maintaining organized cell layers.
• The mechanism by which TSLC1 suppresses tumors, particularly in relation to immune surveillance, requires further elucidation.

Purpose of the Study:

• To investigate the interaction between Necl-2 and cytotoxic lymphocytes.
• To determine if Necl-2 serves as a target for natural killer (NK) cells and CD8+ T cells.
• To explore the role of Necl-2 in tumor suppression mediated by the immune system.

Main Methods:

• Investigated the recognition of Necl-2 by NK cells and CD8+ T cells using the receptor class I-restricted T-cell-associated molecule (CRTAM).
• Assessed the functional consequences of CRTAM-Necl-2 interactions on NK cell cytotoxicity and CD8+ T cell interferon gamma (IFN-gamma) secretion in vitro.
• Evaluated NK cell-mediated rejection of Necl-2-expressing tumors in vivo.

Main Results:

• Demonstrated that NK cells and CD8+ T cells recognize Necl-2 through CRTAM, a receptor expressed on activated immune cells.
• Showed that CRTAM-Necl-2 interactions enhance NK cell cytotoxicity and IFN-gamma secretion by CD8+ T cells.
• Confirmed NK cell-mediated rejection of tumors expressing Necl-2 in vivo.

Conclusions:

• TSLC1/Necl-2 mediates tumor suppression through interactions with cytotoxic lymphocytes (NK cells and CD8+ T cells) via CRTAM.
• Necl-2 acts as a molecular target for immune surveillance, enabling the distinction between tumor cells and normal cells.
• These findings reveal a novel immune-mediated mechanism of tumor suppression involving the TSLC1/Necl-2 pathway.